Physician profile
Krupa Patel
NPI 1205295060
$4,992.68
in general payments reported to CMS, 2019-2025
31 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,436 · 2023: $903 · 2024: $1,440 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.14 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $845.41 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $656.00 | 2022-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $613.49 | 2022-2025 | Lifevest |
| Esperion Therapeutics, INC. | $379.38 | 2024-2025 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $225.98 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $216.04 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $207.85 | 2024-2025 | Wegovy |
| Pfizer INC. | $204.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164.81 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.41 | 2022-2023 | Jardiance |
| Amgen INC. | $143.71 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $134.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.77 | 2024 | |
| Kestra Medical Technology Services, INC. | $116.35 | 2023-2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $97.79 | 2025 | Attruby |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $94.02 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $87.72 | 2022-2025 | Amvuttra |
| Abbott Laboratories | $86.29 | 2022-2024 | Cardiomems |
| Philips North America LLC | $67.03 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Astrazeneca Pharmaceuticals LP | $64.44 | 2023-2025 | Farxiga |
| Boston Scientific Corporation | $40.95 | 2025 | Cds - Mct/Cem Monitoring |
| Cvrx, INC. | $36.08 | 2022 | |
| Medtronic, INC. | $36.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $35.94 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $26.11 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $25.12 | 2025 | |
| Altathera Pharmaceuticals LLC | $23.67 | 2022 | |
| Lantheus Medical Imaging, INC. | $22.66 | 2022 | |
| Abbvie INC. | $21.44 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.81 | 2024 | Arcalyst |
| Itamar Medical INC | $15.22 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krupa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.